MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jama.2025.7817

Медицинская библиотека · JAMA · 2025

Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.

Moscoso Alexis, Heeman Fiona, Raghavan Sheelakumari, Costoya-Sánchez Alejandro, van Essen Martijn, Mainta Ismini, Camacho Valle, Rodríguez-Fonseca Omar, Silva-Rodríguez Jesús, Perissinotti Andrés, Gu Yuna, Yun Jihwan, Peretti Debora, Ribaldi Federica, Coomans Emma M, Brum Wagner S, Grothe Michel J, Aguiar Pablo, Bischof Gérard N, Drzezga Alexander, Seo Sang Won, Villeneuve Sylvia, Malpetti Maura, O'Brien John T, Rowe James B, van de Giessen Elsmarieke M, Ossenkoppele Rik, Jagust William J, Smith Ruben, Hansson Oskar, Frisoni Giovanni B, Garibotto Valentina, Soleimani-Meigooni David N, Carrillo Maria, Dickerson Bradford C, La Joie Renaud, Rabinovici Gil D, Apostolova Liana G, LaMontagne Pamela J, Pontecorvo Michael J, Johnson Keith A, Sperling Reisa A, Weiner Michael W, Petersen Ronald C, Jack Clifford R, Vemuri Prashanthi, Schöll Michael, PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative

СтатьяМногоцентровое исследованиеНаблюдательное исследованиеПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПоддержка правительства СШАПеревод пока не подготовлен

Аннотация

IMPORTANCE

Tau positron emission tomography (PET) allows in vivo detection of neurofibrillary tangles, a core neuropathologic feature of Alzheimer disease (AD).

OBJECTIVE

To provide estimates of the frequency of tau PET positivity and its associated risk of clinical outcomes.

DESIGN, SETTING, AND

PARTICIPANTS

Longitudinal study using data pooled from 21 cohorts, comprising a convenience sample of 6514 participants from 13 countries, collected between January 2013 and June 2024. Cognitively unimpaired individuals and patients with a clinical diagnosis of mild cognitive impairment (MCI), AD dementia, or other neurodegenerative disorders were included.

EXPOSURES: Tau PET with flortaucipir F 18, amyloid-β (Aβ) PET, and clinical examinations. Tau PET scans were visually rated as positive according to a US Food and Drug Administration- and European Medicines Agency-approved method, designed to indicate the presence of advanced neurofibrillary tangle pathology (Braak stages V-VI).

MAIN OUTCOMES AND MEASURES: Frequency of tau PET positivity and absolute risk of clinical progression (eg, progression to MCI or dementia).

RESULTS

Among the 6514 participants (mean age, 69.5 years; 50.5% female), median follow-up time ranged from 1.5 to 4.0 years. Of 3487 cognitively unimpaired participants, 349 (9.8%) were tau PET positive; the estimated frequency of tau PET positivity was less than 1% in those aged younger than 50 years, and increased from 3% (95% CI, 2%-4%) at 60 years to 19% (95% CI, 16%-24%) at 90 years. Tau PET positivity frequency estimates increased across MCI and AD dementia clinical diagnoses (43% [95% CI, 41%-46%] and 79% [95% CI, 77%-82%] at 75 years, respectively). Most tau PET-positive individuals (92%) were also Aβ PET positive. Cognitively unimpaired participants who were positive for both Aβ PET and tau PET had a higher absolute risk of progression to MCI or dementia over the following 5 years (57% [95% CI, 45%-71%]) compared with both Aβ PET-positive/tau PET-negative (17% [95% CI, 13%-22%]) and Aβ PET-negative/tau PET-negative (6% [95% CI, 5%-8%]) individuals. Among participants with MCI at the time of the tau PET scan, an Aβ PET-positive/tau PET-positive profile was associated with a 5-year absolute risk of progression to dementia of 70% (95% CI, 59%-81%).

CONCLUSIONS AND RELEVANCE: In a large convenience sample, a positive tau PET scan occurred at a nonnegligible rate among cognitively unimpaired individuals, and the combination of Aβ PET positivity and tau PET positivity was associated with a high risk of clinical progression in both preclinical and symptomatic stages of AD. These findings underscore the potential of tau PET as a biomarker for staging AD pathology.

Для цитирования: Moscoso Alexis, Heeman Fiona, Raghavan Sheelakumari, Costoya-Sánchez Alejandro, van Essen Martijn, Mainta Ismini, Camacho Valle, Rodríguez-Fonseca Omar, Silva-Rodríguez Jesús, Perissinotti Andrés, Gu Yuna, Yun Jihwan, Peretti Debora, Ribaldi Federica, Coomans Emma M, Brum Wagner S, Grothe Michel J, Aguiar Pablo, Bischof Gérard N, Drzezga Alexander, Seo Sang Won, Villeneuve Sylvia, Malpetti Maura, O'Brien John T, Rowe James B, van de Giessen Elsmarieke M, Ossenkoppele Rik, Jagust William J, Smith Ruben, Hansson Oskar, Frisoni Giovanni B, Garibotto Valentina, Soleimani-Meigooni David N, Carrillo Maria, Dickerson Bradford C, La Joie Renaud, Rabinovici Gil D, Apostolova Liana G, LaMontagne Pamela J, Pontecorvo Michael J, Johnson Keith A, Sperling Reisa A, Weiner Michael W, Petersen Ronald C, Jack Clifford R, Vemuri Prashanthi, Schöll Michael, PREVENT-AD Research Group, the Harvard Aging Brain Study, the LEADS Consortium, and the Alzheimer’s Disease Neuroimaging Initiative. Frequency and Clinical Outcomes Associated With Tau Positron Emission Tomography Positivity.. JAMA. 2025. DOI: 10.1001/jama.2025.7817.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.